Literature DB >> 9778599

Cellular and molecular actions of lamotrigine: Possible mechanisms of efficacy in bipolar disorder.

X Xie1, R M Hagan.   

Abstract

Several clinical studies have investigated the use of the anticonvulsant lamotrigine (LTG) as a treatment for bipolar affective disorder. Evidence suggests that this drug may have a broad spectrum of utility in this illness, having both mood-stabilising (antimanic) and acute antidepressant properties. This makes this molecule of particular interest in helping to understand the underlying disease processes. In this review, we describe the cellular and molecular actions of LTG that may contribute to its action in bipolar disorder. LTG preferentially inhibits neuronal hyperexcitability and modifies synaptic plasticity via use- and voltage-dependent inhibition of neuronal voltage-activated Na+ channels and possibly high-voltage-activated Ca>cf6>2+>cf1> channels. As a consequence, it reduces excessive transmitter release in the brain. Indirectly, these effects would be expected to regulate aberrant intracellular and intercellular signalling in critical regions of the limbic forebrain where hyperactivity may occur in mania, and thus may be directly relevant to its mood-stabilising properties. Whether other molecular actions of LTG, for example on monoamine disposition, could contribute to its antidepressant activity, are less clear at present but warrant further investigation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9778599     DOI: 10.1159/000026527

Source DB:  PubMed          Journal:  Neuropsychobiology        ISSN: 0302-282X            Impact factor:   2.328


  26 in total

1.  Lamotrigine inhibits basal and Na+-stimulated, but not Ca2+-stimulated, release of corticotropin-releasing hormone from the rat hypothalamus.

Authors:  Giuseppe Tringali; Jean Michel Aubry; Pierluigi Navarra; Giacomo Pozzoli
Journal:  Psychopharmacology (Berl)       Date:  2006-09-01       Impact factor: 4.530

Review 2.  Antiepileptic drugs for the treatment of post-traumatic stress disorder.

Authors:  Heather A Berlin
Journal:  Curr Psychiatry Rep       Date:  2007-08       Impact factor: 5.285

3.  Lamotrigine blocks NMDA receptor-initiated arachidonic acid signalling in rat brain: implications for its efficacy in bipolar disorder.

Authors:  Epolia Ramadan; Mireille Basselin; Jagadeesh S Rao; Lisa Chang; Mei Chen; Kaizong Ma; Stanley I Rapoport
Journal:  Int J Neuropsychopharmacol       Date:  2011-06-28       Impact factor: 5.176

Review 4.  Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed?

Authors:  Svein I Johannessen; Torbjörn Tomson
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 5.  The potential role of lamotrigine in schizophrenia.

Authors:  Charles H Large; Elizabeth L Webster; Donald C Goff
Journal:  Psychopharmacology (Berl)       Date:  2005-10-12       Impact factor: 4.530

Review 6.  The Black Book of Psychotropic Dosing and Monitoring.

Authors:  Alan F Schatzberg; DeBattista Charles
Journal:  Psychopharmacol Bull       Date:  2018-01-15

7.  Early effects of mood stabilizers on the Akt/GSK-3beta signaling pathway and on cell survival and proliferation.

Authors:  Jean-Michel Aubry; Michèle Schwald; Eladia Ballmann; Félicien Karege
Journal:  Psychopharmacology (Berl)       Date:  2009-05-14       Impact factor: 4.530

8.  Spotlight on lamotrigine in bipolar disorder.

Authors:  David R Goldsmith; Antona J Wagstaff; Tim Ibbotson; Caroline M Perry
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 9.  Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy.

Authors:  Cecilie Johannessen Landmark
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

10.  Modifications of antiepileptic drugs for improved tolerability and efficacy.

Authors:  Cecilie Johannessen Landmark; Svein I Johannessen
Journal:  Perspect Medicin Chem       Date:  2008-02-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.